Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Breast Cancer

FDA Approves Camizestrant for ESR1‑Mutated Advanced Breast Cancer

The decision lets doctors switch an aromatase inhibitor to the oral SERD camizestrant after a blood test finds an ESR1 resistance mutation, with confirmatory trials required.

3 ARTICLES

2mo ago

AstraZeneca Will Provide Monthly Zoladex Free to Some Australian Patients

11 ARTICLES

2mo ago

Supreme Court Takes Suo Motu Case After Kerala Delay in Cancer Drug Plea

5 ARTICLES

2mo ago

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

8 ARTICLES

2mo ago

Kerala High Court Case on Affordable Ribociclib Listed Again After 57 Postings

4 ARTICLES

3mo ago

Anvisa Approves Inluriyo as Oral Treatment for ER‑Positive, HER2‑Negative, ESR1‑Mutant Advanced Breast Cancer

3 ARTICLES

4mo ago

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

6 ARTICLES

6mo ago

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

3 ARTICLES

9mo ago

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

9 ARTICLES

10mo ago

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

4 ARTICLES

10mo ago

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

8 ARTICLES

last yr.

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

8 ARTICLES

last yr.

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

3 ARTICLES

2y ago

FDA Expands Approval of Kisqali for Early-Stage Breast Cancer